SCOLTA: Surveillance Cohort Long-Term Toxicity Antiretrovirals (Dolutegravir cohort)
Latest Information Update: 29 Mar 2022
At a glance
- Drugs Dolutegravir (Primary)
- Indications HIV infections
- Focus Adverse reactions
- Acronyms SCOLTA
- 16 Feb 2022 Results (n=4751) presented at the 29th Conference on Retroviruses and Opportunistic Infections
- 27 Oct 2017 Results (n=604) assessing tolerability presented at the 16th European AIDS Conference.
- 31 Dec 2016 New trial record